BIO: What’s the ROI on a COVID-19 vaccine? We have no idea, says Pfizer arlene.weintraub Thu, 06/11/2020 – 09:52 More: BIO: What's the ROI on a COVID-19 vaccine? We have no idea, says Pfizer Source: fierce
read moreThe move is Huntsworth’s first acquisition under the ownership of Clayton, Dubilier & Rice More: The Creative Engagement Group buys Cormis Source: News
read moreAbbVie will pay Genmab $750 million upfront, and potentially up to $3.15 billion in additional development, regulatory and sales milestone payments More: AbbVie and Genmab link for oncology collaboration Source: News
read moreThe company aims to target cancer with new drugs that take advantage of protein degradation More: Public launch for ICR, CR UK spinout Monte Rosa Source: News
read moreEvox’ technology modifies exosomes to deliver drugs to areas currently inaccessible More: Lilly signs up for access to Evox' tech in R&D deal Source: News
read moreThe drug did not significantly improve overall survival or progression free survival in the first-line setting More: MSD's Keytruda misses advanced bladder cancer goal Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals